04/04/2026
Bayer has reaffirmed its commitment to simplifying access to innovation in India and supporting early treatment for patients with retinal diseases in India.
More: https://biovoicenews.com/bayer-to-offer-eylea-2mg-to-treat-retinal-diseases-at-lower-cost-in-india/
Eylea 2mg is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina